Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia
A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Provide race and ethnicity information
- Male or female, aged 18 years or greater
- Diagnosed with cancer
- Hospitalized at MCC in the medical, hematologic, or bone marrow transplant units
- Having in-hospital hyperglycemia with or without a pre-existing diagnosis of DM, with 2 measurements of BG > 180 mg/dL and/or 1 measurement of BG > 350mg/dL within the first 72 hours of admission, detected by bedside point-of-care testing and/or basic metabolic panel laboratory data.
- Participants enrolled in other clinical trials are admissible to this trial.
Exclusion Criteria:
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Participants < 18 years of age
- Participants at the end of life and/or with limited life expectancies (< 6 months)
- Participants without cancer diagnoses
- Surgical patients and patients admitted directly to the intensive care unit, other than those in the Bone Marrow Transplant Unit, who are included
- Participants treated and discharged in outpatient settings (ie, direct referral center, infusion center, or clinical research unit) or those admitted for observation only (hospitalized less than 24 hours)
- Participants on total parenteral nutrition
- Participants on insulin pumps
- Participants admitted with diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome
- Pregnant Participants based on medical history
- Participants being followed by endocrinology for hyperglycemia or hypoglycemia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Basal-Prandial-Correctional Insulin Regimen
Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization.
Adjustments will be made in real time to reach the target range.
|
Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
Other Names:
|
|
Active Comparator: Standard of Care Insulin Regimen
Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.
|
Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of blood glucose values within normal range
Time Frame: During hospital admission, up to 30 days
|
Proportion of blood glucose values in the 70 mg/dL to 180 mg/dL (normal) range
|
During hospital admission, up to 30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of high blood glucose levels
Time Frame: During hospital admission, up to 30 days
|
Proportion of blood glucose values >180 mg/dL
|
During hospital admission, up to 30 days
|
|
Proportion of low blood glucose levels
Time Frame: During hospital admission, up to 30 days
|
Proportion of blood glucose values <70 mg/dL
|
During hospital admission, up to 30 days
|
|
Duration of normal blood glucose level
Time Frame: During hospital admission, up to 30 days
|
Duration of blood glucose values in the 70 mg/dL to 180 mg/dL (normal) range
|
During hospital admission, up to 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Smitha Pabbathi, MD, Moffitt Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MCC-19637
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.